. 2022 Jul 18;6(1):e1681. doi: 10.1002/cnr2.1681

TABLE 4.

Cardiac event by number of doxorubicin infusions and time to treatment discontinuation, unadjusted analysis.

Time period		Number of infusions		p‐value ^a	Time to treatment discontinuation ^b		p‐value ^c
Time period		N	Mean (SD) infusions	p‐value ^a	Median days (95% CI)	HR ^c (95% CI)	p‐value ^c
Early period (≤365 days post index)	Patients with no cardiac events	1572	6.0 (4.6)	0.81	69.0 (65.0, 72.0)
Early period (≤365 days post index)	Patients with ≥1 cardiac event	142	5.9 (4.4)	0.81	73.5 (63.0, 86.0)	1.04 (0.88, 1.23)	0.65
Middle period (366–1825 days post index)	Patients with no cardiac events	1622	6.0 (4.5)	0.26	67.0 (65.0, 71.0)
Middle period (366–1825 days post index)	Patients with ≥1 cardiac event	92	6.5 (5.0)	0.26	106.0 (85.0, 108.0)	0.72 (0.58, 0.88)	0.002
Late period (>1825 days post index)	Patients with no cardiac events N	1706	6.0 (4.6)	0.39	69.0 (65.0, 72.0)
Late period (>1825 days post index)	Patients with ≥1 cardiac event	8	7.4 (5.5)	0.39	94.5 (22.0, 113.0)	0.94 (0.47, 1.87)	0.85
Throughout the follow‐up period	Patients with no cardiac events N	1499	6.0 (4.6)	0.75	66.0 (65.0, 71.0)
Throughout the follow‐up period	Patients with ≥1 cardiac event	215	6.1 (4.5)	0.75	85.0 (72.0, 97.0)	0.90 (0.78, 1.03)	0.13

Abbreviations: CI, confidence interval; HR, hazard ratio; SD, standard deviation.

^{^a}

T‐test.

^{^b}

Kaplan Meier estimates.

^{^c}

Cox proportional hazards regression model.